Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Pharmacoepigenetics
- 2nd Edition, Volume 10 - October 25, 2024
- Editor: Ramón Cacabelos
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 7 2 2 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 7 2 3 - 0
Pharmacoepigenetics, Second Edition, Volume Ten in the Translational Epigenetics series, is a comprehensive reference on the role of epigenetics and epigenomics in drug discover… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePharmacoepigenetics, Second Edition, Volume Ten in the Translational Epigenetics series, is a comprehensive reference on the role of epigenetics and epigenomics in drug discovery and development. Here, leading international researchers from across academia, clinical settings, and the pharmaceutical industry discuss the influence of epigenetics and epigenomics in human pathology, epigenetic biomarkers for disease prediction, diagnosis, and treatment, current epigenetic drugs, and the application of epigenetic procedures in drug development. Throughout the book, chapter authors offer a balanced and objective discussion of the future of pharmacoepigenetics and its crucial contribution to the growth of precision and personalized medicine.
This new edition has been fully revised to address recent advances in epigenetics, from new natural and synthetic compounds with epigenetic effects to the role of epigenetics in the pathogenesis of a growing number of complex diseases, including further cancers, cardiovascular disorders, and brain disorders. Newly identified molecular components in the functional architecture of the epigenetic machinery, as well as practical and relevant pharmacoepigenetics topics related to COVID-19 and other world health challenges are also discussed.
This new edition has been fully revised to address recent advances in epigenetics, from new natural and synthetic compounds with epigenetic effects to the role of epigenetics in the pathogenesis of a growing number of complex diseases, including further cancers, cardiovascular disorders, and brain disorders. Newly identified molecular components in the functional architecture of the epigenetic machinery, as well as practical and relevant pharmacoepigenetics topics related to COVID-19 and other world health challenges are also discussed.
- Fully examines the influence of epigenetics and epigenomics in human pathology, epigenetic biomarkers for disease prediction, diagnosis, treatment, current epigenetic drugs, and the application of epigenetic procedures in drug development
- Features chapter contributions from leading international researchers in academia, clinical settings, and the pharmaceutical industry
- Instructs researchers, students, and clinicians in better interpreting and employing pharmacoepigenetics in drug development, efficiency, and safety
- Incorporates recent advances, including epigenetic drugs and biomolecules with epigenetic effects in cancer, cardiovascular disorders, brain disorders, and COVID-19
- Includes chapter definitions, key words, and summaries to reinforce understanding, as well clinical research case studies illustrating key research in the field
Translational researchers, clinicians, and graduate students in genomic medicine and epigenetics, life science researchers, developmental biologists, pharmacologists in industry and academia, Clinicians across specialties
I. General Principles
1.The Epigenetic Machinery in the Life Cycle
2. Pharmacoepigenetics: Basic Principles for Personalized Medicine
3. Pharmacoepigenetic Processors
4. Epigenetic regulation of genes involved in drug metabolism
5. MicroRNA-Dependent Gene Regulation of the Human Cytochromes P450
6. Epigenetic regulation of transporter genes
7. Pathoepigenetics: The Role of Epigenetic Biomarkers in Disease Pathogenesis
II. Drug Development and Drug-related events
8. Epigenetic Drugs
9. Pharmacoepigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors
10. Pharmacoepigenetics: Novel Mechanistic Insights in Drug Discovery and Development Targeting Chromatin-Modifying Enzymes
11. Pharmacoepigenetics of EZH2 Inhibitors
12. Regulators of Histone Acetylation: Bromodomain Inhibitors
13. Bromodomain Inhibition and Its Application to Human Disease
14. Pharmacoepigenetics of Brassica-Derived Compounds
15. Pharmacological Nicotinamide: Mechanisms Centered Around SIRT1 Activity
16. Epigenetic-related Drug Resistance
17. Toxicoepigenetics
III. Pharmacoepigenetics of Cancer
18. Epigenetics of Aging and Cancer: A Comprehensive Look
19. Epigenetic Drug Discovery for Cancer
20. Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
21. Pharmacoepigenetics of LSD1 Inhibitors in Cancer
22. Epigenetic effects of AntiGan in Cancer
23. Pharmacoepigenetic Considerations for the Treatment of Breast Cancer
24. Pharmacoepigenetics of Acute Myeloid Leukemia
25. Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma
26. Pharmacoepigenetics of Gastrointestinal disorders and Cancer
27. Pharmacoepigenetics of Chinese Herbal Components in Cancer
IV. Pharmacoepigenetics of Cardiovascular disease and Related disorders
28. Epigenetics and Pharmacoepigenetics of myocardial infarction
29. Epigenetics and Pharmacoepigenetics of Arteriosclerosis
30. Epigenetics and Pharmacoepigenetics of Hypertension
31. Pharmacoepigenetics of Ancoagulants
32. Epigenetics in Doxorubicin Cardiotoxicity
33. Epigenetic effects of CardioSar in cardiovascular disorders
V. Pharmacoepigenetics of Central Nervous System disorders
34. Epigenetics and Pharmacoepigenetics of Neurodevelopmental and Neuropsychiatric Disorders
35. Pharmacoepigenetics and Toxicoepigenetics in Neurodevelopmental Disorders
36. Pharmacoepigenetics of Autism Spectrum Disorder
37. Pharmacoepigenetics of Antipsychotic Drugs
38. Pharmacoepigenetics of Bipolar Disorder
39. Pharmacoepigenetics of Major Depression
40. Epigenetics and Pharmacoepigenetics of Vestibulocochlear disorders
41. Epigenetics and Pharmacoepigenetics of Visual disorders
42. Epigenetics and Pharmacoepigenetics of Age-Related Neurodegenerative Disorders
43. Epigenetic effects of Nosustrophine in Alzheimer’s disease
44. Epigenetic effects of Atremorine in Parkinson’s disease
45. Pharmacoepigenetics and Pharmacoepigenomics of Valproate in Neurodegenerative Disease
46. Pharmacoepigenetics of Memantine in Dementia
VI. Pharmacoepigenetics of Metabolic and Endocrine disorders
47. Pharmacoepigenetics in Type 2 Diabetes Mellitus
48. Epigenetics and Pharmacoepigenetics of hypercholesterolemia and lipid metabolism disorders
49. Pharmacoepigenetics of Statins
50. Epigenetics and Pharmacoepigenetics of Thyroid disorders
VII. Pharmacoepigenetics of Immunological and Inflammatory disorders
51. Pharmacoepigenetics of Immunological Disorders
52. Pharmacoepigenetics of Rheumatic Disorders
53. Epigenetics and Pharmacoepigenetics of Skin disorders
54. Pharmacoepigenetics of Systemic Lupus Erythematosus
VIII. Nutritional Epigenetics
55. Nutriepigenetics
56. Epinutraceuticals: Novel biomolecules with epigenetic effects
IX. Epigenetics and Pharmacoepigenetics of infectious disorders
57. Pharmacoepigenetic of bacterial infections
58. Pharmacoepigenetics of viral infections
59. Pharmacoepigenetics of COVID-19
X. Mendelian epigenetic disorders
60. Pharmacoepigenetics of Mendelian disorders associated with the epigenetic machinery
1.The Epigenetic Machinery in the Life Cycle
2. Pharmacoepigenetics: Basic Principles for Personalized Medicine
3. Pharmacoepigenetic Processors
4. Epigenetic regulation of genes involved in drug metabolism
5. MicroRNA-Dependent Gene Regulation of the Human Cytochromes P450
6. Epigenetic regulation of transporter genes
7. Pathoepigenetics: The Role of Epigenetic Biomarkers in Disease Pathogenesis
II. Drug Development and Drug-related events
8. Epigenetic Drugs
9. Pharmacoepigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors
10. Pharmacoepigenetics: Novel Mechanistic Insights in Drug Discovery and Development Targeting Chromatin-Modifying Enzymes
11. Pharmacoepigenetics of EZH2 Inhibitors
12. Regulators of Histone Acetylation: Bromodomain Inhibitors
13. Bromodomain Inhibition and Its Application to Human Disease
14. Pharmacoepigenetics of Brassica-Derived Compounds
15. Pharmacological Nicotinamide: Mechanisms Centered Around SIRT1 Activity
16. Epigenetic-related Drug Resistance
17. Toxicoepigenetics
III. Pharmacoepigenetics of Cancer
18. Epigenetics of Aging and Cancer: A Comprehensive Look
19. Epigenetic Drug Discovery for Cancer
20. Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
21. Pharmacoepigenetics of LSD1 Inhibitors in Cancer
22. Epigenetic effects of AntiGan in Cancer
23. Pharmacoepigenetic Considerations for the Treatment of Breast Cancer
24. Pharmacoepigenetics of Acute Myeloid Leukemia
25. Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma
26. Pharmacoepigenetics of Gastrointestinal disorders and Cancer
27. Pharmacoepigenetics of Chinese Herbal Components in Cancer
IV. Pharmacoepigenetics of Cardiovascular disease and Related disorders
28. Epigenetics and Pharmacoepigenetics of myocardial infarction
29. Epigenetics and Pharmacoepigenetics of Arteriosclerosis
30. Epigenetics and Pharmacoepigenetics of Hypertension
31. Pharmacoepigenetics of Ancoagulants
32. Epigenetics in Doxorubicin Cardiotoxicity
33. Epigenetic effects of CardioSar in cardiovascular disorders
V. Pharmacoepigenetics of Central Nervous System disorders
34. Epigenetics and Pharmacoepigenetics of Neurodevelopmental and Neuropsychiatric Disorders
35. Pharmacoepigenetics and Toxicoepigenetics in Neurodevelopmental Disorders
36. Pharmacoepigenetics of Autism Spectrum Disorder
37. Pharmacoepigenetics of Antipsychotic Drugs
38. Pharmacoepigenetics of Bipolar Disorder
39. Pharmacoepigenetics of Major Depression
40. Epigenetics and Pharmacoepigenetics of Vestibulocochlear disorders
41. Epigenetics and Pharmacoepigenetics of Visual disorders
42. Epigenetics and Pharmacoepigenetics of Age-Related Neurodegenerative Disorders
43. Epigenetic effects of Nosustrophine in Alzheimer’s disease
44. Epigenetic effects of Atremorine in Parkinson’s disease
45. Pharmacoepigenetics and Pharmacoepigenomics of Valproate in Neurodegenerative Disease
46. Pharmacoepigenetics of Memantine in Dementia
VI. Pharmacoepigenetics of Metabolic and Endocrine disorders
47. Pharmacoepigenetics in Type 2 Diabetes Mellitus
48. Epigenetics and Pharmacoepigenetics of hypercholesterolemia and lipid metabolism disorders
49. Pharmacoepigenetics of Statins
50. Epigenetics and Pharmacoepigenetics of Thyroid disorders
VII. Pharmacoepigenetics of Immunological and Inflammatory disorders
51. Pharmacoepigenetics of Immunological Disorders
52. Pharmacoepigenetics of Rheumatic Disorders
53. Epigenetics and Pharmacoepigenetics of Skin disorders
54. Pharmacoepigenetics of Systemic Lupus Erythematosus
VIII. Nutritional Epigenetics
55. Nutriepigenetics
56. Epinutraceuticals: Novel biomolecules with epigenetic effects
IX. Epigenetics and Pharmacoepigenetics of infectious disorders
57. Pharmacoepigenetic of bacterial infections
58. Pharmacoepigenetics of viral infections
59. Pharmacoepigenetics of COVID-19
X. Mendelian epigenetic disorders
60. Pharmacoepigenetics of Mendelian disorders associated with the epigenetic machinery
- No. of pages: 1150
- Language: English
- Edition: 2
- Volume: 10
- Published: October 25, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443187223
- eBook ISBN: 9780443187230
RC
Ramón Cacabelos
Dr. Ramón Cacabelos is Professor and Chairman of Genomic Medicine and President of the EuroEspes Biomedical Research Center, Corunna, Spain. He received his M.D. from Oviedo University, Oviedo, Spain; Ph.D. from Santiago University, Santiago de Compostela, Spain; and D.M.Sci. (Psychiatry) from Osaka University Medical School, Osaka, Japan. After a decade at the Department of Psychiatry in Osaka, he returned to Spain and focused his research activity on the genomics, epigenomics and pharmacogenomics of brain disorders, with special emphasis on neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease). He has published over 700 papers and 30 books and is Editor-in-Chief of the first World Guide for Drug Use and Pharmacogenomics and President of the World Association of Genomic Medicine.
Affiliations and expertise
Professor of Genomic Medicine, Visiting Professor of Health Science, Aino University, Osaka, Japan, President, World Association of Genomic Medicine, President, Spanish Society of Genomic Medicine